Welcome to our dedicated page for Soleno Therapeutics news (Ticker: SLNO), a resource for investors and traders seeking the latest updates and insights on Soleno Therapeutics stock.
News about Soleno Therapeutics, Inc. (NASDAQ: SLNO) centers on its work as a biopharmaceutical company developing and commercializing novel therapeutics for rare diseases, with a primary focus on Prader-Willi syndrome (PWS) and hyperphagia. Company press releases highlight clinical, regulatory, commercial, and corporate developments related to its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets.
Readers following SLNO news can find updates on VYKAT XR, a once-daily oral treatment indicated for hyperphagia in adults and pediatric patients 4 years of age and older with PWS. News items include details of the Phase 3 clinical program, such as the randomized withdrawal study published in the Journal of Clinical Endocrinology and Metabolism, which Soleno reports supported FDA approval as the first treatment for hyperphagia in people living with PWS.
Soleno’s news flow also covers financial results and launch metrics for VYKAT XR, including product revenue from U.S. sales, patient start forms, prescriber adoption, coverage levels, and commentary on achieving profitability and positive cash flow. Investors can track announcements about preliminary and full-quarter results, conference call schedules, and corporate presentations.
Additional news topics include capital allocation and corporate actions, such as the Board-authorized $100 million accelerated share repurchase agreement, amendments to loan facilities, and Board and Audit Committee changes. The company also issues communications on safety and regulatory matters, including an 8-K describing a serious adverse event reported in the FDA’s FAERS database and Soleno’s assessment of that case.
For those monitoring SLNO, this news stream provides insight into Soleno’s rare disease strategy, the commercial trajectory of VYKAT XR in PWS, and key corporate and regulatory milestones disclosed through press releases and SEC-referenced communications.
Soleno Therapeutics (NASDAQ: SLNO) announced participation in three investor conferences in November 2025 with dates, times, formats, and webcast availability.
Events: Guggenheim Securities Healthcare Innovation Conference on Nov 11, 2025 at 9:00 AM ET (fireside chat); Stifel 2025 Healthcare Conference on Nov 12, 2025 at 8:40 AM ET (fireside chat); and Jefferies London Healthcare Conference on Nov 18, 2025 at 5:00 PM GMT (presentation). Replays will be posted in the investor section at www.soleno.life.
Soleno Therapeutics (NASDAQ: SLNO) will report third quarter 2025 financial results and operational highlights after the U.S. market close on Tuesday, November 4, 2025.
The company will host a live conference call and webcast at 4:30 PM Eastern Time on that date. Dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (international) with Conference ID 48794. A webcast will be available on the company website and replayable for 30 days.
Soleno Therapeutics (NASDAQ: SLNO) announced the appointment of biopharmaceutical finance executive Mark W. Hahn to its Board of Directors and as a member of its Audit Committee, increasing the Board to seven members.
Mr. Hahn brings nearly 30 years of CFO-level experience across life sciences companies, including roles that covered product launches, financings and M&A. His background includes serving as CFO of Verona Pharma through its phase 3 program and launch and its acquisition by Merck for approximately $10 billion (Oct 2025), and as CFO of Dova Pharmaceuticals through its sale for up to $915 million (Nov 2019). Soleno noted the hire aligns with its ongoing commercial launch of VYKAT™ XR and named Mr. Hahn as Audit Committee member.
Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company focused on rare disease therapeutics, has announced its participation in five major healthcare investor conferences during September 2025.
The company will present at the Cantor Global Healthcare Conference (Sept 3), Wells Fargo Healthcare Conference (Sept 4), H.C. Wainwright Global Investment Conference (Sept 8), Baird Global Healthcare Conference (Sept 9), and Bernstein Healthcare Forum (Sept 25). All presentations will be in fireside chat format.
Webcasts for the Cantor and Wells Fargo events will be available for replay on Soleno's website.
Soleno Therapeutics (NASDAQ:SLNO) reported significant progress in Q2 2025, highlighted by the successful launch of VYKAT XR, the first FDA-approved therapy for Prader-Willi Syndrome (PWS). Since its April 14 launch, the company has received 646 patient start forms from 295 unique prescribers, with coverage extending to over 100 million lives.
The company reported Q2 2025 product revenue of $32.7 million and ended the quarter with $293.8 million in cash and equivalents. Additionally, Soleno raised $230 million through a stock offering in July. The company's Marketing Authorization Application (MAA) for VYKAT XR has been submitted to the European Medicines Agency (EMA) for PWS treatment approval in the EU.
Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company focused on rare diseases, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after market close. The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates.
The press release also includes important safety information for VYKAT XR, their treatment for hyperphagia in Prader-Willi syndrome (PWS) patients aged 4 and older. Key safety considerations include monitoring for hyperglycemia and fluid overload, with the most common adverse reactions being hypertrichosis, edema, hyperglycemia, and rash.
Soleno Therapeutics (NASDAQ: SLNO) has announced the pricing of its public offering of 2,352,941 shares of common stock at $85.00 per share, aiming to raise approximately $200 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to 352,941 additional shares.
The proceeds will primarily fund the commercialization of VYKATT™ XR, their recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome patients. Additional funds will support EU regulatory activities, research and development, and general corporate purposes. The offering, managed by Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer, is expected to close around July 11, 2025.
Soleno Therapeutics (NASDAQ:SLNO) has announced plans for a $200 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to $30 million of shares. The offering will be managed jointly by Goldman Sachs and Guggenheim Securities.
The proceeds will primarily fund the commercialization of VYKAT™ XR, their recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome. Additional funds will support EU regulatory activities, research and development, and general corporate purposes. The offering will be made through a previously filed Form S-3ASR registration statement.
Soleno Therapeutics (Nasdaq: SLNO) released preliminary Q2 2025 financial results, highlighting strong performance of its recently approved drug VYKAT™ XR. The company projects Q2 net revenue between $31.0-$33.0 million from VYKAT™ XR sales.
Key metrics include $293.8 million in cash and equivalents, 646 patient start forms from 295 unique prescribers since VYKAT™ XR's March 26 approval, and $50.0 million in outstanding debt. The company notes these results are preliminary and subject to final review.
Soleno Therapeutics (NASDAQ: SLNO) announced two presentations featuring their drug VYKAT™ XR (diazoxide choline) for Prader-Willi Syndrome at the upcoming ENDO 2025 conference in San Francisco. The presentations will be delivered by Dr. Ashley Shoemaker from Vanderbilt University Medical Center.
The first presentation will discuss glycemic outcomes of the drug over a 4-year period, scheduled as an oral presentation on July 14, 2025. The second presentation, in poster format, will focus on characterizing peripheral edema in patients during long-term administration over 4.5 years.